Med-Fine Capital

Med-Fine Capital is a Shanghai-based venture capital firm specializing in early-stage investments in the healthcare and life sciences sectors across China. The firm focuses on identifying and supporting high-potential companies developing breakthrough medical technologies, including biotechnology, medical devices, diagnostics, digital health, and healthcare services. Med-Fine Capital manages both RMB and USD-denominated funds, enabling it to support companies with both domestic and international growth paths.

The firm's investment strategy emphasizes early-stage value discovery, targeting seed to late-stage opportunities with a focus on sectors such as oncology, autoimmune, metabolic, and central nervous system diseases. Med-Fine Capital aims to be a long-term strategic partner to its portfolio companies, providing not only capital but also strategic guidance and access to a global network of resources. The firm has invested in over 60 companies, including Mabworks, Eccogene, Zion, LYNK, Pharma Legacy, MagAssist, Alebund, Allorion, ImmVira, Degron, Allink, and Castalysis.

Med-Fine Capital's leadership team combines deep industry knowledge with a strong global network and proven investment capabilities. The team is led by Managing Partner Jack Zhou and Dr. Vince Deng, Partner and Head of Biotech Investment. The firm's approach is grounded in deep scientific diligence and a long-term commitment to advancing patient outcomes, aiming to build a research-driven investment system rooted in clinical value and technological innovation, with global market value in mind and meeting unmet medical needs as the end game.